MSKCC Risk Stratification Model in RCC Updated to Include Genomic Information
Three genes were confirmed to have prognostic value in RCC and were integrated into the MSKCC risk model toward the creation of a new, genomically annotated model.
All articles by Alexander M. Castellino, PhD
The Changing Treatment Landscape for Advanced Renal Cell Carcinoma
Interferon or high-dose interleukin-2 were the only available options for the treatment of metastatic RCC until 2005.
Guideline Updates on Quality Palliative Care
A draft guideline from the National Consensus Project for Quality Palliative Care describes best practices for caring for individuals who are seriously ill.
Prognostic Model for Survival in Metastatic Prostate Cancer
Utilizing data from the PREVAIL dataset, researchers developed mathematical models that can provide prognostic information for men being treated with enzalutamide for chemotherapy-naïve metastatic castration-resistant prostate cancer.
The Immune Landscape in Metastatic Breast Cancer Is “More Inert”
Researchers compared the immune microenvironments of primary tumors with those at sites of metastases.
Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
A matching-adjusted indirect comparison concluded that ponatinib offers better disease control compared with bosutinib in certain patients.
A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
Humans are used to seeing canines used as tools in forensics — their skills are often harnessed to smell out drugs or trail a criminal. Some dogs are even used to locate household pests. The use of canines to detect lung cancer from smell alone, however, is a new prospect for oncologists and their patients.
“Impressive” CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
A preplanned exploratory analysis in a subset of patients from the phase 3 FLAURA study with CNS metastases at baseline shows “impressive” clinical activity in the CNS.
Novel Approaches for the Treatment of Primary Central Nervous System Lymphoma
A review published in Blood highlights new approaches that are being investigated to treat PCNSL based on the mutational landscape and signaling pathways that are extant in the disease.
Janus Kinase Inhibitors for the Treatment of Myelofibrosis
The identification of driver mutations in myelofibrosis has helped cement understanding of the pathophysiology of the disease and has kick-started the development of targeted therapies.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...